NCT07202429Completed
Additive Role of ADC Value to ORADS in Adnexal Lesions
Additive Role of Mean Apparent Diffusion Coefficient (ADCmean) Value Measurements to the Ovarian-Adnexal Reporting and Data System (O-RADS) MRI Score in Stratifications of Adnexal Lesions
Source: ClinicalTrials.gov · Last updated 1 Oct 2025
Brief summary (registry, in English)
Evaluation of the impact of adding mean apparent diffusion coefficient (ADC mean) measurements to the Ovarian-Adnexal Imaging Reporting and Data System MRI (O-RADS MRI) scoring for adnexal lesion characterization using a combined O-RADS MRI/ADC mean reading approach.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 66 (actual)
- First submitted
- 6 Sept 2023
- Start date
- 1 Mar 2023
- Primary completion date
- 1 Jun 2024
- Lead sponsor
- Cairo University
- Diseases
- Ovarian cancer, Childhood cancers
- NCT number
- NCT07202429
What you commit to
- Study type: Observational
- Participants enrolled: 66
- From 1 Mar 2023 to the primary completion date, 1 Jun 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous bilateral adnexectomy.
Other illness
- Contraindications to MRI examination including
- Absolute contraindications: such as The cardiac implantable electronic device (CIED), Metallic intraocular foreign bodies, ….)
- Relative contraindications: such as Coronary and peripheral artery stents, Ocular prosthesis,……)
Age
- Female patient any age with adnexal lesions detected by U/S reported as O-RADS1and2.
Other
- Cysts that were deemed to be clearly physiological and less than 3 cm in maximum diameter.
- No histopathological findings or follow-up \< one year .
Who the study is looking for
- (1) Female patient any age with at least one adnexal lesion detected by U/S reported as O-RADS3to5.
- (2) The interval between operation and ultrasonography did not exceed 120 days. (3) Subsequent surgery with histological examination or stability at follow-up imaging for at least 1 year.
- (4) For bilateral adnexal masses, the mass with the most complex features was included.
- (5)If two masses had similar morphologies, the largest mass was included.
Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Kasr Al-Ainy Faculty of Medicine, Cairo University Coordinator of this site? Confirm its status | Cairo | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.